Canakinumab for systemic-onset juvenile idiopathic arthritis/Still’s disease—effectiveness and safety data from the BiKeR registry

ABSTRACT: Objectives: In Germany, canakinumab is approved for the treatment of refractory systemic juvenile idiopathic arthritis (sJIA)/Still’s disease. This study assesses the experience of sJIA/Still’s disease patients treated with canakinumab in clinical practice. Methods: Data of 79 sJIA/Still’...

Ausführliche Beschreibung

Bibliografische Detailangaben

Hauptverfasser:	Gerd Horneff, Tilmann Kallinich, Kirsten Minden, Frank Dressler, Markus Hufnagel, Frank Weller-Heinemann, Ariane Klein
Format:	Artigo
Sprache:	Inglês
Veröffentlicht:	Elsevier 2026-06-01
Schriftenreihe:	EULAR Rheumatology Open
Online-Zugang:	http://www.sciencedirect.com/science/article/pii/S3050708125001107
Tags:	Tag hinzufügen Keine Tags, Fügen Sie das erste Tag hinzu!